SK155694A3 - Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters - Google Patents

Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters Download PDF

Info

Publication number
SK155694A3
SK155694A3 SK1556-94A SK155694A SK155694A3 SK 155694 A3 SK155694 A3 SK 155694A3 SK 155694 A SK155694 A SK 155694A SK 155694 A3 SK155694 A3 SK 155694A3
Authority
SK
Slovakia
Prior art keywords
glu
gly
ala
ser
derivative
Prior art date
Application number
SK1556-94A
Other languages
English (en)
Slovak (sk)
Inventor
Glenn C Andrews
Gaston O Daumy
Michael L Francoeur
Eric R Larson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK155694A3 publication Critical patent/SK155694A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SK1556-94A 1992-06-15 1993-04-14 Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters SK155694A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89907392A 1992-06-15 1992-06-15
PCT/US1993/003388 WO1993025579A1 (fr) 1992-06-15 1993-04-14 Derives d'insulinotropine et de peptide analogue au glucagon

Publications (1)

Publication Number Publication Date
SK155694A3 true SK155694A3 (en) 1995-05-10

Family

ID=25410453

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1556-94A SK155694A3 (en) 1992-06-15 1993-04-14 Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters

Country Status (19)

Country Link
EP (2) EP0969016A2 (fr)
JP (1) JP2575298B2 (fr)
KR (1) KR0154880B1 (fr)
CN (1) CN1057098C (fr)
AU (1) AU671117B2 (fr)
BR (1) BR9306551A (fr)
CA (1) CA2138161C (fr)
CZ (1) CZ315594A3 (fr)
FI (1) FI932722L (fr)
HR (1) HRP930993A2 (fr)
HU (2) HUT64367A (fr)
IL (1) IL105928A0 (fr)
MX (1) MX9303554A (fr)
NO (1) NO944853D0 (fr)
PL (1) PL176007B1 (fr)
RU (1) RU2128663C1 (fr)
SK (1) SK155694A3 (fr)
WO (1) WO1993025579A1 (fr)
YU (1) YU41493A (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
AU4415796A (en) * 1994-12-07 1996-06-26 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5747453A (en) 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69941510D1 (de) 1998-08-10 2009-11-19 Us Gov Nat Inst Health Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
EP1992641A3 (fr) * 1998-12-07 2009-07-29 Ipsen Pharma Analogues GLP-1
CZ295044B6 (cs) * 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP2213743A1 (fr) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Protéines de fusion d'albumine
CA2430934C (fr) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. Procede de production de preparations d'une substance bioactive a liberation prolongee a l'aide de gaz haute pression
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
PL209734B1 (pl) 2002-02-20 2011-10-31 Emisphere Tech Inc Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
AU2005203925A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
HRP20060362A2 (en) 2004-04-23 2007-03-31 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
EP2590997B1 (fr) * 2010-07-09 2018-04-04 Dana-Farber Cancer Institute, Inc. Peptides insulinotropes stabilisés et procédés d'utilisation
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
WO2017210100A1 (fr) * 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Conjugués peptide apparenté au glucagon-1-t3
LT3541366T (lt) 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai
MX2019010651A (es) * 2017-03-08 2020-01-13 Intarcia Therapeutics Inc Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE193541T1 (de) * 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
EP0499990B1 (fr) * 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Procédé pour la production des peptides sans cystéine
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK39892D0 (da) * 1992-03-25 1992-03-25 Bernard Thorens Peptid

Also Published As

Publication number Publication date
HU211498A9 (en) 1995-11-28
PL176007B1 (pl) 1999-03-31
IL105928A0 (en) 1993-10-20
BR9306551A (pt) 1998-09-15
CN1057098C (zh) 2000-10-04
WO1993025579A1 (fr) 1993-12-23
CN1085913A (zh) 1994-04-27
KR950701937A (ko) 1995-05-17
FI932722A7 (fi) 1993-12-16
YU41493A (sh) 1996-10-18
NO944853L (no) 1994-12-14
RU94046251A (ru) 1996-10-27
EP0646128A1 (fr) 1995-04-05
CA2138161A1 (fr) 1993-12-23
JP2575298B2 (ja) 1997-01-22
HUT64367A (en) 1993-12-28
CZ315594A3 (en) 1995-07-12
HRP930993A2 (en) 1996-12-31
FI932722L (fi) 1993-12-16
EP0969016A2 (fr) 2000-01-05
AU4027593A (en) 1994-01-04
JPH07504679A (ja) 1995-05-25
KR0154880B1 (ko) 1998-10-15
MX9303554A (es) 1994-06-30
HU9301739D0 (en) 1993-09-28
FI932722A0 (fi) 1993-06-14
RU2128663C1 (ru) 1999-04-10
AU671117B2 (en) 1996-08-15
NO944853D0 (no) 1994-12-14
CA2138161C (fr) 2003-10-21

Similar Documents

Publication Publication Date Title
SK155694A3 (en) Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
JP3759748B2 (ja) 成長ホルモン放出性を有する化合物
AU2017216533B2 (en) Improved peptide pharmaceuticals
US6921748B1 (en) Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
KR101205272B1 (ko) 아실화된 ｇｌｐ-1 화합물
CN102197049B (zh) 胰岛淀粉样多肽衍生物
KR20220133304A (ko) 인크레틴 유사체 및 그의 용도
WO2009034119A1 (fr) Dérivés améliorés de l'amyline
WO2014049610A2 (fr) Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon
KR20190097299A (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
CA2335341A1 (fr) Analogues peptidiques des pacap
US8383581B2 (en) Short-chain peptides as parathyroid hormone (PTH) receptor agonist
CN103124739B (zh) 一种新胰高血糖素样肽类似物、组合物及其用途
JP2026505071A (ja) Ｇｉｐ／ｇｌｐ１／ｇｃｇ三受容体アゴニスト及びそれらの使用
JP2011525895A (ja) アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
CN112608378A (zh) 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用
JPH0769919A (ja) Ｖｉｐ，その類縁体またはそのフラグメントを含む医薬組成物
CN100503637C (zh) 胰高血糖素样肽类似物、其组合物及其使用方法
TWI428139B (zh) A novel glucagon-like peptide analogue, a composition and use thereof